Top Page | English | 简体中文 | 繁體中文 | 한국어 | 日本語
Friday, 19 January 2018, 13:35 HKT/SGT
Share:
    

Source: Eisai
Eisai: Oral Antifungal Agent NAILIN Capsules 100mg Approved in Japan

TOKYO, Jan 19, 2018 - (JCN Newswire) - Sato Pharmaceutical Co., Ltd. obtained marketing and manufacturing approval for the oral antifungal agent NAILIN Capsules 100mg containing the active ingredient fosravuconazole L-lysine ethanolate (fosravuconazole) for the treatment of onychomycosis in Japan on January 19, 2018.

Sato Pharma and Eisai Co., Ltd. are jointly providing information on its proper use.

Fosravuconazole, the active ingredient of NAILIN Capsules 100mg, is a new triazole class oral antifungal component discovered by Eisai. Sato Pharma conducted a Phase III clinical study of the agent in patients with onychomycosis in Japan, and after confirming efficacy and safety of the agent in the study, Sato Pharma applied for marketing and manufacturing authorization in January 2017.

Onychomycosis affects 1 in every 10 Japanese people, and there are an estimated approximately 11 million sufferers in Japan. With Sato Pharma now having obtained marketing and manufacturing approval for NAILIN Capsules 100mg, as an oral treatment for onychomycosis, this is the first new treatment for the disease in approximately 20 years.

By providing NAILIN Capsules 100mg as a new option for the treatment of onychomycosis, Sato Pharma and Eisai will strive to fulfil the needs of onychomycosis patients and healthcare professionals.


About Eisai

Eisai Co., Ltd. is a leading global research and development-based pharmaceutical company headquartered in Japan. We define our corporate mission as "giving first thought to patients and their families and to increasing the benefits health care provides," which we call our human health care (hhc) philosophy. With approximately 10,000 employees working across our global network of R&D facilities, manufacturing sites and marketing subsidiaries, we strive to realize our hhc philosophy by delivering innovative products in various therapeutic areas with high unmet medical needs, including Oncology and Neurology.

As a global pharmaceutical company, our mission extends to patients around the world through our investment and participation in partnership-based initiatives to improve access to medicines in developing and emerging countries.

For more information about Eisai Co., Ltd., please visit https://www.eisai.com.

Contact:
Public Relations Department,
Eisai Co., Ltd.
+81-3-3817-5120


Jan 19, 2018 13:35 HKT/SGT
Source: Eisai

Eisai (TSE: 4523)

Topic: Press release summary
Sectors: BioTech
http://www.acnnewswire.com
From the Asia Corporate News Network


Copyright © 2018 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.



Eisai
July 31, 2018 14:13 HKT/SGT
Eisai Signs Collaboration Agreement for Anti-Obesity Agent Lorcaserin in China to CY Biotech
July 31, 2018 10:27 HKT/SGT
Eisai and Merck & Co., Inc., Kenilworth, N.J., U.S.A. Announce U.S. FDA Grants Breakthrough Therapy Designation for LENVIMA
July 26, 2018 10:34 HKT/SGT
Eisai and Biogen Announce Detailed Results of Phase II Clinical Study of BAN2401 in Early Alzheimer's Disease at AAIC 2018
July 26, 2018 08:01 HKT/SGT
Eisai and Biogen Present Detailed Results from Phase II Clinical Study of Elenbecestat in MCI and Mild to Moderate Alzheimer's Disease at AAIC 2018
July 19, 2018 09:38 HKT/SGT
Latest Data on Eisai's Alzheimer's Disease / Dementia Pipeline to be Presented at Alzheimer's Association International Conference (AAIC) 2018
July 18, 2018 11:04 HKT/SGT
Eisai: Positive Topline Results Obtained from Large-Scale Cardiovascular Outcomes Trial of Anti-Obesity Agent BELVIQ
July 11, 2018 15:32 HKT/SGT
Eisai: Oral Antifungal Agent Nailin Capsules 100mg to be Launched in Japan
July 10, 2018 10:14 HKT/SGT
Eisai: Oral Presentation on Phase II Clinical Study Results of BAN2401 to be Presented at Alzheimer's Association International Conference (AAIC) 2018
July 9, 2018 14:07 HKT/SGT
Eisai: Results from Two Phase 3 Clinical Trials of Chronic Constipation Treatment "GOOFICE 5mg Tablet" Published in The Lancet Gastroenterology & Hepatology
July 6, 2018 09:31 HKT/SGT
Eisai and Biogen Announce Positive Topline Results of the Final Analysis for BAN2401 At 18 Months
More news >>
 News Alerts
Copyright © 2018 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Privacy Policy | Terms of Use | RSS
US: +1 800 291 0906 | Beijing: +86 10 8405 3688 | Hong Kong: +852 2217 2912 | Singapore: +65 6304 8926 | Tokyo: +81 3 6721 7212

Connect With us: